IL-2 and Zoledronic Acid Therapy Restores the In Vivo Anti-Leukemic Activity of Human Lymphocytes Pre-Exposed to Simulated Microgravity
AffiliationSchool of Nutritional Sciences and Wellness, University of Arizona
Department of Pediatrics, University of Arizona
Department of Immunobiology, University of Arizona
University of Arizona Cancer Center
MetadataShow full item record
CitationMylabathula, P. L., Diak, D. M., Baker, F. L., Niemiro, G. M., Markofski, M. M., Crucian, B. E., Katsanis, E., & Simpson, R. J. (2022). IL-2 and Zoledronic Acid Therapy Restores the In Vivo Anti-Leukemic Activity of Human Lymphocytes Pre-Exposed to Simulated Microgravity. Frontiers in Bioscience (Landmark Edition), 27(7), 215.
RightsCopyright © 2022 The Author(s). Published by IMR Press. This is an open access article under the CC BY 4.0 license.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBACKGROUND: We have previously shown that the anti-tumor activity of human lymphocytes is diminished in vitro after 12-hours pre-exposure to simulated microgravity (SMG). Here we used an immunocompromised mouse model to determine if this loss of function would extend in vivo, and to also test the efficacy of IL-2 and zoledronic acid (ZOL) therapy as a potential countermeasure against SMG-induced immune dysfunction. We adoptively transferred human lymphocytes that were exposed to either SMG or 1G-control into NSG-Tg (Hu-IL15) mice 1-week after they were injected with a luciferase-tagged human chronic myeloid leukemia (K562) cell line. Tumor growth was monitored 2x weekly with bioluminescence imaging (BLI) for up to 6-weeks. RESULTS: Mice that received lymphocytes exposed to SMG showed greater tumor burden compared to those receiving lymphocytes exposed to 1G (week 6 BLI: 1.8e10 ± 8.07e9 versus 2.22e8 ± 1.39e8 photons/second; p < 0.0001). Peak BLI was also higher in the SMG group compared to 1G-control (2.34e10 ± 1.23e10 versus 3.75e8 ± 1.56e8 photons/second; p = 0.0062). Exposure to SMG did not affect the ability of human lymphocytes to engraft or evoke xeno-graft-versus-host disease in the mice. Additionally, we injected the mice with IL-2 and zoledronic acid (ZOL) to expand and activate the anti-tumor activity of NK cells and γ δ-T cells, respectively. This treatment was found to revive the loss of anti-leukemic function observed in vivo when lymphocytes were pre-exposed to SMG. CONCLUSIONS: Microgravity plays a contributory role in loss of tumor control in vivo. Immuno-stimulating agents like ZOL+IL-2 may offer an important countermeasure for immune dysregulation during prolonged spaceflight. © 2022 The Author(s). Published by IMR Press.
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as Copyright © 2022 The Author(s). Published by IMR Press. This is an open access article under the CC BY 4.0 license.
- T cell resistance to activation by dendritic cells requires long-term culture in simulated microgravity.
- Authors: Bradley JH, Stein R, Randolph B, Molina E, Arnold JP, Gregg RK
- Issue date: 2017 Nov
- Effects of simulated microgravity on primary human NK cells.
- Authors: Li Q, Mei Q, Huyan T, Xie L, Che S, Yang H, Zhang M, Huang Q
- Issue date: 2013 Aug
- Detrimental effects of simulated microgravity on mast cell homeostasis and function.
- Authors: Kim M, Jang G, Kim KS, Shin J
- Issue date: 2022
- The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
- Authors: Xun CQ, Thompson JS, Jennings CD, Brown SA
- Issue date: 1995 Oct 27
- Vaccination efficacy with marrow mesenchymal stem cell against cancer was enhanced under simulated microgravity.
- Authors: Li J, Chen J, Li X, Qian Y
- Issue date: 2017 Apr 8